Buprenorphine and naloxone interactions in opiate-dependent volunteers

被引:57
作者
Mendelson, J
Jones, RT
Fernandez, I
Welm, S
Melby, AK
Baggott, MJ
机构
[1] Drug Dependence Research Center, Langley Porter Psychiatric Institute, University of California, San Francisco, CA
[2] Drug Dependence Research Center, Langley Porter Psychiatric Institute, Univ. of California, San Francisco, San Francisco, CA 94143-0984
关键词
D O I
10.1016/S0009-9236(96)90173-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Sublingual buprenorphine appears useful in the treatment of opiate dependence, A combination sublingual dose of buprenorphine and naloxone could have less potential for parenteral use by opiate-dependent individuals. To estimate the abuse potential of a combination formulation, we assessed the parenteral effects of a buprenorphine and naloxone combination in untreated heroin addicts, Methods: Eight healthy, opiate-dependent daily users of heroin were given, under double-blind conditions on four separate occasions, either (1) 2 mg buprenorphine, (2) 2 mg naloxone, (3) 2 mg buprenorphine and 2 mg naloxone combined, or (4) placebo as a single intravenous infusion during a 30-second interval. Opiate agonist and antagonist physiologic and subjective effects were measured. Data were analyzed by analysis of variance, Results: Buprenorphine increased opiate intoxication and relieved withdrawal, The buprenorphine and naloxone combination precipitated opiate withdrawal and was unpleasant and dysphoric in all subjects, Fifty percent of the subjects were unable to distinguish between naloxone alone and the combined medications during the first hour of testing. Conclusions: The buprenorphine and naloxone combination has a low abuse potential in opiate-dependent daily heroin users.
引用
收藏
页码:105 / 114
页数:10
相关论文
共 27 条
[1]   A CLINICAL-TRIAL OF BUPRENORPHINE - COMPARISON WITH METHADONE IN THE DETOXIFICATION OF HEROIN-ADDICTS [J].
BICKEL, WK ;
STITZER, ML ;
BIGELOW, GE ;
LIEBSON, IA ;
JASINSKI, DR ;
JOHNSON, RE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (01) :72-78
[2]  
CHOWDHURY AN, 1990, BRIT J ADDICT, V85, P1349
[3]  
*DHHS PUBL HLTH SE, 1994, EP TRENDS DRUG AB, V1, P38
[4]   ANALYSIS OF EPIDEMIOLOGICAL DATA ON AGONIST-ANTAGONIST ANALGESICS [J].
GHODSE, AH .
DRUG AND ALCOHOL DEPENDENCE, 1987, 20 (04) :375-383
[5]  
HAMMERSLEY R, 1990, BRIT J ADDICT, V85, P301
[6]   SUBLINGUAL VERSUS SUBCUTANEOUS BUPRENORPHINE IN OPIATE ABUSERS [J].
JASINSKI, DR ;
FUDALA, PJ ;
JOHNSON, RE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (05) :513-519
[7]   A CONTROLLED TRIAL OF BUPRENORPHINE TREATMENT FOR OPIOID DEPENDENCE [J].
JOHNSON, RE ;
JAFFE, JH ;
FUDALA, PJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (20) :2750-2755
[8]   USE OF BUPRENORPHINE IN THE TREATMENT OF OPIATE ADDICTION .1. PHYSIOLOGIC AND BEHAVIORAL-EFFECTS DURING A RAPID DOSE INDUCTION [J].
JOHNSON, RE ;
CONE, EJ ;
HENNINGFIELD, JE ;
FUDALA, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (03) :335-343
[9]   OPIOID ANTAGONIST CHALLENGES IN BUPRENORPHINE MAINTAINED PATIENTS [J].
KOSTEN, TR ;
KRYSTAL, JH ;
CHARNEY, DS ;
PRICE, LH ;
MORGAN, CH ;
KLEBER, HD .
DRUG AND ALCOHOL DEPENDENCE, 1990, 25 (01) :73-78
[10]   TREATMENT OF HEROIN-ADDICTS USING BUPRENORPHINE [J].
KOSTEN, TR ;
MORGAN, C ;
KLEBER, HD .
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 1991, 17 (02) :119-128